SCHEMBL14218512

SCHEMBL14218512

CC1(C)CC2N(C(=O)c3c[nH]c4cc5c(cc34)OCO5)CC2(C)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR1A P08908 1/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR1E P28566 1/20 0.35
HTR1F P30939 1/20 0.35
HTR7 P34969 1/20 0.35
HTR2B P41595 1/20 0.35
HTR3A P46098 1/20 0.35
HTR5A P47898 1/20 0.35
HTR6 P50406 1/20 0.35
HTR4 Q13639 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
RAB9A P51151 4/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13668451 0.83 LMNA (0.48) SMN1; SMN2LMNAALDH1A1AVPR1AAVPR2
SCHEMBL14218452 0.81 CNR2 (0.44) HTR2AHTR7ALDH1A1KDM4ECNR2
SCHEMBL14218514 0.81 NR4A2 (0.45) RAB9ALMNAAVPR1AKDM4ENPSR1
SCHEMBL14218585 0.80 F7 (0.48)
SCHEMBL14218479 0.78 NR4A2 (0.50) HTR4RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL14218586 0.78 TUBB1 (0.50) SMN1; SMN2ALDH1A1KDM4ENPC1MAPT
SCHEMBL14218551 0.78 MEN1 (0.45) ALDH1A1MEN1KMT2ACNR2
SCHEMBL14218513 0.73 HPGD (0.45) HTR1DSMN1; SMN2LMNAALDH1A1KDM4E
SCHEMBL13672423 0.70 AVPR2 (0.38) HTR2AHTR2CHTR2BLMNAALDH1A1
SCHEMBL14218550 0.70 CNR2 (0.45) LMNAAVPR1AAVPR2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108598-A1 Pharmaceutical use of substituted amides NOVO NORDISK A/S (DK) 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108598-A1 Pharmaceutical use of substituted amides HSD11B1, HSD3B1, HSD11B2 HTR3E 1608/4885HTR3B 1371/4885HTR1A 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.